Last Updated on January 4, 2024 by The Health Master
Stempeutics, a group company of Manipal Education and Medical Group (MEMG), said it has received Drugs Controller General of India (DCGI) clearance to conduct a Phase 3 clinical trial on its product for treating COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).
The company will be using its stem cell product, Stempeucel, for conducting the label extension Phase 3 clinical trial.
The product is already approved for marketing for the treatment of critical limb ischemia by the Drugs Controller General of India (DCGI).
Stempeucel exhibits potent immuno-modulatory and anti-inflammatory properties which could help in reducing the inflammation caused due to the cytokine storm elicited by the body’s immune cells in response to SARS-CoV-2 (COVID-19) related infection in the lungs, Stempeutics said in a statement.
“Coronavirus third wave appears to be mild-to-moderate. But the most severely affected CoV-2 infected patients will often go on to develop ARDS which necessitates assisted ventilation to preserve breathing and lung function.
“Moreover, many ARDS patients may also experience an acute inflammatory response (cytokine storm) which can result in long-term damage to lung tissue and lung function,” Stempeutics Chairman Sudarshan Ballal noted.
Treating ARDS patients with allogeneic expanded bone marrow derived MSCs could alleviate lung inflammation and compromised lung function and significantly reduce the time required for patients to be ventilated, he stated.
“The results of this trial would be very crucial in confirming this,” Ballal said.
Headquartered in Bengaluru, Stempeutics is an advanced clinical-stage biotech company.
Pharmaceutical Budget 2022: Expectations
NPPA to conduct study on Price Regulatory Policies in these 10 countries
IPC flags safety alert against Covid-19 drug Remdesivir
FDA alerts Medical Officers to maintain healthy Oxygen status
Which medicine works best for Covid-19 treatment? WHO answers
Govt notifies New Drugs and Clinical Trials (Amendment) Rules 2022
Drug recall: Sun Pharma, Lupin recall these drugs
BIS notifies new standard for these Medical Devices
Latest Notifications: Medical Devices
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
